Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy

Arai, Yasuyuki; Aoki, Kazunari; Takeda, June; Kondo, Tadakazu; Eto, Tetsuya; Ota, Shuichi; Hashimoto, Hisako; Fukuda, Takahiro; Ozawa, Yukiyasu; Kanda, Yoshinobu; Kato, Chiaki; Kurokawa, Mineo; Iwato, Koji; Onizuka, Makoto; Ichinohe, Tatsuo; Atsuta, Yoshiko; Takami, Akiyoshi

doi:10.1186/s13045-015-0201-x

Table 1 Patient characteristics

From: Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy

Variables		Total		CY/TBI		HDCA/CY/TBI
Variables		N = 2102	%	N = 1667	%	N = 435	%	p
Sex	Male	1205	57.3	959	57.5	246	56.5
Sex	Female	897	42.7	708	42.5	189	43.5	0.71
Age	Median (years)	38		38		38		0.10
	(Range)	(16–64)		(16–62)		(16–64)
	≤49	1762	83.8	1391	83.4	371	85.3
	≥50	340	16.2	276	16.6	64	14.7	0.35
PS	0–1	1963	93.3	1577	94.6	386	88.7
	≥2	104	5.0	62	3.7	42	9.7
	Unknown	35	1.7	28	1.7	7	1.6	<0.01^*
HCT-CI	≤2	1287	61.2	1024	61.4	263	60.5
	≥3	111	5.3	90	5.4	21	4.8
	Unknown	704	33.5	553	33.2	151	34.7	0.78
CMV sero-status	Negative	392	18.7	312	18.7	80	18.4
	Positive	1524	72.4	1221	73.3	303	69.6
	Unknown	186	8.9	134	8.0	52	12.0	0.04^*
Diagnosis	AML	1808	86.0	1397	83.8	411	94.5
Diagnosis	MDS	294	14.0	270	16.2	24	5.5	<0.01^*
Disease risk	Standard	1276	60.7	1074	64.4	202	46.4
Disease risk	High	826	39.3	593	35.6	233	53.6	<0.01^*
(In AML)	Standard	1191	65.9	993	71.1	198	48.2
(In AML)	High	617	34.1	404	28.9	213	51.8	<0.01^*
(In MDS)	Standard	85	28.9	81	30.0	4	16.7
(In MDS)	High	209	71.1	189	70.0	20	83.3	0.17
Days from diagnosis to HCT	Median	239		240		237		0.03^*
	≤240	1056	50.2	834	50.0	222	51.0
	≥241	1046	49.8	833	50.0	213	49.0	0.71
Donor source	Rel-BM	455	21.7	351	21.1	104	23.9
	Rel-PB	499	23.7	386	23.2	113	26.0
	UR-BM	1148	54.6	930	55.7	218	50.1	0.11
Graft cell dose	BM (NCC, median)	2.69 × 10⁸/kg		2.66 × 10⁸/kg		2.77 × 10⁸/kg		0.27
Graft cell dose	PB (CD34⁺ cell count, median)	3.99× 10⁶/kg		4.00× 10⁶/kg		3.67× 10⁶/kg		0.52
HLA mismatch	Matched	1343	63.9	1057	63.4	286	65.7
HLA mismatch	Mismatched	759	36.1	610	36.6	149	34.3	0.37
Sex mismatch	Matched	1145	54.4	919	55.1	226	51.9
	M to F	508	24.2	398	23.9	110	25.3
	F to M	445	21.2	346	20.8	99	22.8
	Unknown	4	0.2	4	0.2	0	0.0	0.45
ABO mismatch	Matched	1114	53.0	888	53.3	226	52.0
	Minor	389	18.5	305	18.3	84	19.3
	Major	354	16.8	287	17.2	67	15.4
	Both	186	8.9	148	8.9	38	8.7
	Unknown	59	2.8	39	2.3	20	4.6	0.12
GVHD prophylaxis	CyA based	1033	49.1	816	49.0	217	49.9
GVHD prophylaxis	Tac based	1069	50.9	851	51.0	218	50.1	0.73
Year of HCT	≤2008	1107	52.7	875	52.5	232	53.3
Year of HCT	≥2009	995	47.3	792	47.5	203	46.7	0.75
Follow-up period	Median	1134		1130		1171.5		0.11
Follow-up period	(Range)	(40–4947)		(40–4922)		(41–4947)

CY cyclophosphamide, TBI total-body irradiation, HDCA high-dose cytarabine, PS performance status, HCT-CI hematopoietic cell transplant co-morbidity index, CMV cytomegalovirus, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, Rel related donor, UR unrelated donor, BM bone marrow graft, PB peripheral blood stem cell graft, NCC nucleated cell count, HLA human leukocyte antigen, M to F male to female, F to M female to male, GVHD graft-versus-host disease, CyA cyclosporine, Tac tacrolimus
^*Indicates statistically significant by the χ ² test or Student’s t test

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Hematology & Oncology

Contact us